companydata.dkcompanydata.dk

UCB NORDIC A/S: Financial statements 2021

CVR: 26688949

Source: annual report 2021, Danish Business Authority

01/01/2021 – 31/12/2021

UCB NORDIC A/S (CVR 26688949) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK 60,527,000 and a net result of DKK 3,016,000 compared with DKK 3,721,000 the year before. That is an increase of 31% compared with the year before. Equity in the 2021 report amounted to DKK 14,114,000. The solvency ratio was 23.8%. The company had 40 employees in the financial year.

Gross Profit
DKK 60,527,000
Profit/Loss
DKK 3,016,000
Equity
DKK 14,114,000
Total Assets
DKK 59,202,000
Employees
40

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2021-60.5M3M14.1M40
2020-46.2M3.7M11.1M31
2019-39.5M3.6M10.6M26
2018-34.6M3.3M10.3M24
2017-34.8M3.7M10.6M23

Official annual report

View the official annual report directly on the page with a Pro subscription.

Find more companies like UCB NORDIC A/S

Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.

Try the lead list generator

Events in 2021

UCB NORDIC A/S appoints new auditorJul 13, 2021

As of July 13, 2021, Forvis Mazars Statsautoriseret Revisionspartnerselskab has been appointed auditor of UCB NORDIC A/S.

Auditor steps down at UCB NORDIC A/SJul 13, 2021

As of July 13, 2021, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of UCB NORDIC A/S.

UCB NORDIC A/S: The 2020 annual report is outJun 11, 2021

UCB NORDIC A/S has published its annual report for 2020. Gross profit came to DKK 46,217,000, and the net result was DKK 3,721,000.

About UCB NORDIC A/S

UCB NORDIC A/S is a Danish company of the type Aktieselskab based in København S, founded in 2002. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named UCB NORDICS ApS and CELLTECH NORDIC ApS. The management consists of Mari-Ann Retz. The board consists of Laura Ann Byram (chair), Christina Dyreborg Jeppesen and Jaana Mattila. The company is owned by UCB Pharma SA. The company has 48 employees (2026). In 2025, the company reported a gross profit of DKK 88,278,000 and a net result of DKK 6,014,000 compared with DKK 5,226,000 the year before. Equity in the 2025 report amounted to DKK 18,047,000.

Source: annual report 2025, Danish Business Authority